Key points from article :
Insilico Medicine used Microsoft BioGPT, a large language model trained on biomedical data, to identify 9 potential dual-purpose targets against ageing and 14 age-related diseases.
Two of the proposed genes have not been previously correlated to the ageing process, indicating the potential of Transformer models in novel target prediction.
Insilico Medicine operates as a clinical-stage drug discovery company, employing its proprietary Pharma.AI platform.
Their focus lies in the development of innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) ailments, and ageing-related diseases.
The findings were published in the journal Aging.
